JP2019513780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513780A5 JP2019513780A5 JP2018553953A JP2018553953A JP2019513780A5 JP 2019513780 A5 JP2019513780 A5 JP 2019513780A5 JP 2018553953 A JP2018553953 A JP 2018553953A JP 2018553953 A JP2018553953 A JP 2018553953A JP 2019513780 A5 JP2019513780 A5 JP 2019513780A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hearing loss
- ear
- platinum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- 206010011878 Deafness Diseases 0.000 claims 6
- 231100000888 hearing loss Toxicity 0.000 claims 6
- 230000010370 hearing loss Effects 0.000 claims 6
- 208000016354 hearing loss disease Diseases 0.000 claims 6
- 208000027601 Inner ear disease Diseases 0.000 claims 4
- 229950005951 azasetron Drugs 0.000 claims 4
- 208000032625 disorder of ear Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052697 platinum Inorganic materials 0.000 claims 4
- 206010011891 Deafness neurosensory Diseases 0.000 claims 3
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 231100000879 sensorineural hearing loss Toxicity 0.000 claims 3
- 208000023573 sensorineural hearing loss disease Diseases 0.000 claims 3
- 208000027491 vestibular disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 231100000199 ototoxic Toxicity 0.000 claims 2
- 230000002970 ototoxic effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- DBMKBKPJYAHLQP-UHFFFAOYSA-N Azasetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C DBMKBKPJYAHLQP-UHFFFAOYSA-N 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 208000017119 Labyrinth disease Diseases 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 208000022949 middle ear disease Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000023088 sudden sensorineural hearing loss Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 description 3
- 210000003454 tympanic membrane Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 2
- 230000001720 vestibular Effects 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000005077 saccule Anatomy 0.000 description 1
- 210000002480 semicircular canal Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322690P | 2016-04-14 | 2016-04-14 | |
| US62/322,690 | 2016-04-14 | ||
| EP16180192.3 | 2016-07-19 | ||
| EP16180192 | 2016-07-19 | ||
| PCT/EP2017/059058 WO2017178645A1 (en) | 2016-04-14 | 2017-04-14 | (+)-azasetron for use in the treatment of ear disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513780A JP2019513780A (ja) | 2019-05-30 |
| JP2019513780A5 true JP2019513780A5 (https=) | 2021-08-12 |
| JP7158723B2 JP7158723B2 (ja) | 2022-10-24 |
Family
ID=65588799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018553953A Active JP7158723B2 (ja) | 2016-04-14 | 2017-04-14 | 耳疾患の処置における使用のための（＋）－アザセトロン |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11612605B2 (https=) |
| EP (1) | EP4335508A3 (https=) |
| JP (1) | JP7158723B2 (https=) |
| CN (1) | CN109310698B (https=) |
| AU (1) | AU2023202897B2 (https=) |
| CL (1) | CL2018002930A1 (https=) |
| DK (1) | DK3442537T3 (https=) |
| ES (1) | ES2975016T3 (https=) |
| FI (1) | FI3442537T3 (https=) |
| HR (1) | HRP20240453T1 (https=) |
| HU (1) | HUE066000T2 (https=) |
| IL (1) | IL262305B (https=) |
| MX (1) | MX384045B (https=) |
| NZ (1) | NZ747201A (https=) |
| PL (1) | PL3442537T3 (https=) |
| RS (1) | RS65379B1 (https=) |
| SI (1) | SI3442537T1 (https=) |
| ZA (1) | ZA201806894B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847489B (zh) * | 2015-05-18 | 2021-09-17 | 森索睿翁公司 | 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| US5360800A (en) | 1987-09-03 | 1994-11-01 | Glaxo Group Limited | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
| CA1304082C (en) | 1987-10-22 | 1992-06-23 | Tetsuya Tahara | Benzoxazine compounds and pharmaceutical use thereof |
| GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| GB0009914D0 (en) | 2000-04-20 | 2000-06-07 | Metris Therapeutics Limited | Device |
| GB0104554D0 (en) | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New uses |
| US20030044356A1 (en) | 2001-04-20 | 2003-03-06 | Jin Auh | Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one) |
| WO2003071986A2 (en) | 2002-02-22 | 2003-09-04 | Control Delivery Systems, Inc. | Method for treating otic disorders |
| GB0213869D0 (en) | 2002-06-17 | 2002-07-31 | Arakis Ltd | The treatment of pain |
| JP2006516977A (ja) | 2003-01-13 | 2006-07-13 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
| MY143789A (en) | 2003-02-18 | 2011-07-15 | Helsinn Healthcare Sa | Use of palonosetron treating post- operative nausea and vomiting |
| US20040204466A1 (en) | 2003-04-14 | 2004-10-14 | Orchid Chemicals And Pharmaceuticals Ltd. | Treatment of bronchial asthma using 5-HT3 receptor antagonists |
| US20070265329A1 (en) | 2006-05-12 | 2007-11-15 | Devang Shah T | Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) |
| EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| AU2009271129B2 (en) * | 2008-07-14 | 2013-10-10 | Otonomy, Inc. | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders |
| DK2432467T3 (en) * | 2009-05-20 | 2018-04-16 | Inst Nat Sante Rech Med | SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS |
| ES2432618T3 (es) | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular |
| CN101786963B (zh) | 2010-03-03 | 2013-05-08 | 山东众诚药业股份有限公司 | 阿扎司琼中间体的合成方法 |
| WO2013124416A1 (en) | 2012-02-23 | 2013-08-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Calcineurin inhibitors for use in the treatment of lesional vestibular disorders |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| BR112016002205A2 (pt) * | 2013-07-31 | 2017-08-01 | Bluepharma Ind Farmaceutica S A | filmes orodispersíveis |
| CN104557906A (zh) | 2015-01-21 | 2015-04-29 | 扬子江药业集团四川海蓉药业有限公司 | 一种盐酸阿扎司琼的制备方法 |
| CN107847489B (zh) | 2015-05-18 | 2021-09-17 | 森索睿翁公司 | 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂 |
-
2017
- 2017-04-14 MX MX2018012587A patent/MX384045B/es unknown
- 2017-04-14 PL PL17717441.4T patent/PL3442537T3/pl unknown
- 2017-04-14 EP EP23220392.7A patent/EP4335508A3/en not_active Withdrawn
- 2017-04-14 ES ES17717441T patent/ES2975016T3/es active Active
- 2017-04-14 SI SI201731500T patent/SI3442537T1/sl unknown
- 2017-04-14 RS RS20240412A patent/RS65379B1/sr unknown
- 2017-04-14 DK DK17717441.4T patent/DK3442537T3/da active
- 2017-04-14 HU HUE17717441A patent/HUE066000T2/hu unknown
- 2017-04-14 US US16/093,911 patent/US11612605B2/en active Active
- 2017-04-14 NZ NZ747201A patent/NZ747201A/en unknown
- 2017-04-14 CN CN201780036585.4A patent/CN109310698B/zh active Active
- 2017-04-14 JP JP2018553953A patent/JP7158723B2/ja active Active
- 2017-04-14 FI FIEP17717441.4T patent/FI3442537T3/fi active
- 2017-04-14 HR HRP20240453TT patent/HRP20240453T1/hr unknown
-
2018
- 2018-10-11 IL IL262305A patent/IL262305B/en unknown
- 2018-10-12 CL CL2018002930A patent/CL2018002930A1/es unknown
- 2018-10-16 ZA ZA2018/06894A patent/ZA201806894B/en unknown
-
2023
- 2023-03-13 US US18/182,511 patent/US20230226071A1/en active Pending
- 2023-05-09 AU AU2023202897A patent/AU2023202897B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2469726C2 (ru) | Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней | |
| RU2499592C2 (ru) | Фармацевтическая композиция для лечения ушных заболеваний | |
| JP2019524657A5 (https=) | ||
| ES2909395T3 (es) | Fomento del crecimiento del cabello y tratamiento de la pérdida del cabello o caída excesiva del cabello | |
| EP4523752A3 (en) | Film formulations containing dexmedetomidine and methods of producing them | |
| US20100298440A1 (en) | 1-aminocyclohexane derivatives for the treatment of hearing loss | |
| JP2022506062A5 (https=) | ||
| JP2015212268A5 (https=) | ||
| JP2015532296A5 (https=) | ||
| JP2015511609A5 (https=) | ||
| JP2014065696A5 (https=) | ||
| JP2020530831A5 (https=) | ||
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2015516988A5 (https=) | ||
| RU2020108192A (ru) | Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf | |
| JP2019509253A5 (https=) | ||
| JP2019518022A5 (https=) | ||
| RU2019138166A (ru) | Средство для профилактики или лечения атрофии головного мозга | |
| JP2016530238A5 (https=) | ||
| JP2025502064A5 (https=) | ||
| US11690830B2 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| JP2019513780A5 (https=) | ||
| KR102429935B1 (ko) | 귀 장애의 치료에 사용하기 위한 (+)-아자세트론 | |
| JP2023531930A5 (https=) |